Free Delivery Over $100
|
|
|||
|
||||
OverviewRepaglinide is a novel prandial glucose regulator (PGR) for the treatment of type 2 diabetes mellitus. Repaglinide is mainly metabolised in the liver by CYP3A4 and CYP2o enzymes. The objective of the study is to investigate the effects of the CYP3A4 and CYP2o genotypes on the pharmacokinetics of repaglinide in 121 healthy Malaysian subjects. Initially, a new HPLC method using a simple liquid-liquid extraction for the determination of repaglinide in human serum was developed and later validated. Then, PCR methods were optimized to detect CYP3A4 and CYP2o genetic polymorphisms among healthy Malaysian subjects. Each subject received 4 mg of oral repaglinide. Six blood samples per individual were taken (0 min, 30 min, 60 min, 120 min, 180 min and 240 min) for repaglinide's serum concentration determination by using HPLC. NPAG was then used to determine population pharmacokinetic parameter values of repaglinide. Full Product DetailsAuthor: Ruzilawati AbU BakarPublisher: VDM Verlag Dr. Muller Aktiengesellschaft & Co. KG Imprint: VDM Verlag Dr. Muller Aktiengesellschaft & Co. KG Dimensions: Width: 22.90cm , Height: 1.50cm , Length: 15.20cm Weight: 0.404kg ISBN: 9783639251296ISBN 10: 3639251296 Pages: 272 Publication Date: 27 June 2010 Audience: General/trade , General Format: Paperback Publisher's Status: Active Availability: In Print  This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us. Table of ContentsReviewsAuthor InformationTab Content 6Author Website:Countries AvailableAll regions |
||||
